---
document_datetime: 2025-12-03 14:18:42
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/nexobrid-epar-all-authorised-presentations_en.pdf
document_name: nexobrid-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.6802092
conversion_datetime: 2025-12-14 22:31:10.467609
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name   | Strength   | Pharmaceutical Form    | Route of Administration   | Immediate Packaging                       | Content (concentration)   | Pack size         |
|------------------|-------------------|------------|------------------------|---------------------------|-------------------------------------------|---------------------------|-------------------|
| EU/1/12/803/ 002 | NexoBrid          | 5 G        | Powder and gel for gel | Cutaneous use             | powder: vial (glass); gel: bottle (glass) | powder: 5 g; gel: 50 g    | 1 vial + 1 bottle |